Global Transient Ischemic Attack Treatment Market 2025 by Company, Regions, Type and Application, Forecast to 2031
Description
According to our (Global Info Research) latest study, the global Transient Ischemic Attack Treatment market size was valued at US$ 7213 million in 2024 and is forecast to a readjusted size of USD 9756 million by 2031 with a CAGR of 4.4% during review period.
Transient ischemic attack (TIA) is a common cerebrovascular disease, known as a "minor stroke", and is an important warning signal for stroke. TIA is defined medically as a clinical symptom of focal neurological deficits caused by transient blood supply disorders to the brain, typically lasting within 1 hour, and with no evidence of acute cerebral infarction on imaging examinations. The treatment of TIA usually includes drug therapy, surgical treatment, and rehabilitation therapy. For non cardiogenic TIA patients, antiplatelet therapy is the cornerstone of acute phase drug therapy, and commonly used drugs include aspirin and clopidogrel. For TIA caused by cardioembolic embolism, anticoagulant therapy is the first choice, with representative drugs including warfarin, dabigatran, rivaroxaban, etc. For TIA patients with symptomatic carotid stenosis, carotid endarterectomy (CEA) and carotid artery stenting (CAS) are the main methods. Rehabilitation treatment includes blood pressure control, blood lipid regulation, blood glucose management, lifestyle intervention, and other aspects.
This report is a detailed and comprehensive analysis for global Transient Ischemic Attack Treatment market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Transient Ischemic Attack Treatment market size and forecasts, in consumption value ($ Million), 2020-2031
Global Transient Ischemic Attack Treatment market size and forecasts by region and country, in consumption value ($ Million), 2020-2031
Global Transient Ischemic Attack Treatment market size and forecasts, by Type and by Application, in consumption value ($ Million), 2020-2031
Global Transient Ischemic Attack Treatment market shares of main players, in revenue ($ Million), 2020-2025
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Transient Ischemic Attack Treatment
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Transient Ischemic Attack Treatment market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Bayer, Sanofi, Bristol Myers Squibb, Pfizer, Novartis, AstraZeneca, Roche, Siemens Healthineers, Johnson and Johnson, Boehringer Ingelheim, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market segmentation
Transient Ischemic Attack Treatment market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Drug Treatment
Surgical Treatment
Rehabilitation
Others
Market segment by Application
Atherosclerotic Transient Ischemic Attack
Cardioembolic Transient Ischemic Attack
Hemodynamic Transient Ischemic Attack
Market segment by players, this report covers
Bayer
Sanofi
Bristol Myers Squibb
Pfizer
Novartis
AstraZeneca
Roche
Siemens Healthineers
Johnson and Johnson
Boehringer Ingelheim
Stryker
Boston Scientific
Terumo
Medtronic
Tasly Pharmaceutical Group
Shenzhen Salubris Pharmaceuticals
CSPC Pharmaceutical Group
Simcere Pharmaceutical Group
Market segment by regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Transient Ischemic Attack Treatment product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Transient Ischemic Attack Treatment, with revenue, gross margin, and global market share of Transient Ischemic Attack Treatment from 2020 to 2025.
Chapter 3, the Transient Ischemic Attack Treatment competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2020 to 2031
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2020 to 2025.and Transient Ischemic Attack Treatment market forecast, by regions, by Type and by Application, with consumption value, from 2026 to 2031.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Transient Ischemic Attack Treatment.
Chapter 13, to describe Transient Ischemic Attack Treatment research findings and conclusion.
Transient ischemic attack (TIA) is a common cerebrovascular disease, known as a "minor stroke", and is an important warning signal for stroke. TIA is defined medically as a clinical symptom of focal neurological deficits caused by transient blood supply disorders to the brain, typically lasting within 1 hour, and with no evidence of acute cerebral infarction on imaging examinations. The treatment of TIA usually includes drug therapy, surgical treatment, and rehabilitation therapy. For non cardiogenic TIA patients, antiplatelet therapy is the cornerstone of acute phase drug therapy, and commonly used drugs include aspirin and clopidogrel. For TIA caused by cardioembolic embolism, anticoagulant therapy is the first choice, with representative drugs including warfarin, dabigatran, rivaroxaban, etc. For TIA patients with symptomatic carotid stenosis, carotid endarterectomy (CEA) and carotid artery stenting (CAS) are the main methods. Rehabilitation treatment includes blood pressure control, blood lipid regulation, blood glucose management, lifestyle intervention, and other aspects.
This report is a detailed and comprehensive analysis for global Transient Ischemic Attack Treatment market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Transient Ischemic Attack Treatment market size and forecasts, in consumption value ($ Million), 2020-2031
Global Transient Ischemic Attack Treatment market size and forecasts by region and country, in consumption value ($ Million), 2020-2031
Global Transient Ischemic Attack Treatment market size and forecasts, by Type and by Application, in consumption value ($ Million), 2020-2031
Global Transient Ischemic Attack Treatment market shares of main players, in revenue ($ Million), 2020-2025
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Transient Ischemic Attack Treatment
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Transient Ischemic Attack Treatment market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Bayer, Sanofi, Bristol Myers Squibb, Pfizer, Novartis, AstraZeneca, Roche, Siemens Healthineers, Johnson and Johnson, Boehringer Ingelheim, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market segmentation
Transient Ischemic Attack Treatment market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Drug Treatment
Surgical Treatment
Rehabilitation
Others
Market segment by Application
Atherosclerotic Transient Ischemic Attack
Cardioembolic Transient Ischemic Attack
Hemodynamic Transient Ischemic Attack
Market segment by players, this report covers
Bayer
Sanofi
Bristol Myers Squibb
Pfizer
Novartis
AstraZeneca
Roche
Siemens Healthineers
Johnson and Johnson
Boehringer Ingelheim
Stryker
Boston Scientific
Terumo
Medtronic
Tasly Pharmaceutical Group
Shenzhen Salubris Pharmaceuticals
CSPC Pharmaceutical Group
Simcere Pharmaceutical Group
Market segment by regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Transient Ischemic Attack Treatment product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Transient Ischemic Attack Treatment, with revenue, gross margin, and global market share of Transient Ischemic Attack Treatment from 2020 to 2025.
Chapter 3, the Transient Ischemic Attack Treatment competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2020 to 2031
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2020 to 2025.and Transient Ischemic Attack Treatment market forecast, by regions, by Type and by Application, with consumption value, from 2026 to 2031.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Transient Ischemic Attack Treatment.
Chapter 13, to describe Transient Ischemic Attack Treatment research findings and conclusion.
Table of Contents
130 Pages
- 1 Market Overview
- 2 Company Profiles
- 3 Market Competition, by Players
- 4 Market Size Segment by Type
- 5 Market Size Segment by Application
- 6 North America
- 7 Europe
- 8 Asia-Pacific
- 9 South America
- 10 Middle East & Africa
- 11 Market Dynamics
- 12 Industry Chain Analysis
- 13 Research Findings and Conclusion
- 14 Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
